Bluelake Biotechnology 2/6/23 Bluelake Biotechnology 2/6/23

Blue Lake Biotechnology to highlight preliminary COVID Phase 1 data at BIO CEO Conference

Guest User 11/7/22 Guest User 11/7/22

Blue Lake Biotechnology Announces Positive Interim Phase 1 Data for BLB201 Intranasal RSV Vaccine

Guest User 10/31/22 Guest User 10/31/22

Another Tool in the Fight Against COVID-19

from UGA Today

Guest User 7/27/22 Guest User 7/27/22

CyanVac CEO Speaks at White House Summit on the Future of COVID-19 Vaccines

Guest User 7/21/22 Guest User 7/21/22

Blue Lake Biotechnology Announces First Participant Dosed in a Phase 1 Clinical Trial of Its BLB-201 Intranasal RSV Vaccine

Guest User 6/13/22 Guest User 6/13/22

Nasal Vaccines Are Commercially High Risk, Perhaps High Reward

from The Scientist

Guest User 6/9/22 Guest User 6/9/22

CyanVac Announces Data from Preclinical Studies of Intranasal PIV5-based COVID-19 Vaccine Candidate CVXGA1

Guest User 5/24/22 Guest User 5/24/22

Blue Lake Biotechnology Announces FDA Fast Track Designation for BLB-201 Intranasal RSV Vaccine

Guest User 4/20/22 Guest User 4/20/22

Professor moves closer to possible COVID-19 vaccine

from UGA Today

Guest User 4/10/22 Guest User 4/10/22

The next leap in coronavirus vaccine development could be a nasal spray

from Washington Post

Guest User 3/28/22 Guest User 3/28/22

CyanVac and Blue Lake Biotechnology Announce FDA Clearance of IND Application for BLB-201 Intranasal RSV Vaccine

Guest User 9/28/21 Guest User 9/28/21

CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine

Guest User 3/24/21 Guest User 3/24/21

CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US